Equecabtagene Autoleucel: Equecabtagene Autoleucel (CT103A) is a novel fully human BCMA-targeting CAR-T therapy
Study summary
This study is a multicenter, observational, single-arm real world study. The purpose of this study is to describe demographic and disease characteristics, treatment patterns, and clinical outcomes in the real-world setting among participants in China with relapsed/refractory multiple myeloma (RRMM) who have been treated with Equecabtagene Autoleucel. This study will use both prospective and retrospective data
Eligibility
Sex
ALL
Min age
18 Years
Max age
—
Healthy volunteers
No
Inclusion Criteria:
* Adult patients with confirmed relapsed/refractory multiple myeloma;
* Based on clinical practice, the physician decided to administer equecabtagene autoleucel treatment;
* Voluntarily sign the informed consent form approved by the ethics committee.
Exclusion Criteria:
* Patients who are hypersensitive to the active ingredients of the product or any excipients (dimethyl sulfoxide, compound electrolyte injection, human albumin);
* The researcher believes that patients are unable to return for follow-up visits or that it is impossible to complete the study;
* Patients with expected survival less than 3 months
Primary outcome measure(s)
Best Overall Response Rate， BOR — up to 24 weeks Patients treatmented with Equecabtagene Autoleucel, the optimal disease state evaluated by the researcher is strict complete response (sCR),complete response (CR), very good partial response (Very Good Partial Response (VGPR) or partial response (partial response,PR) rate.
Trial sites (1)
Facility
City
Region
Status
Peking University People's Hospital
Beijing
China
Official registry record
This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.
We use cookies to analyse site traffic and improve your experience. With your consent, we may also use cookies for advertising. You can change your choice at any time on our Cookie Policy page. See also our Privacy Policy.